Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients

Eloxx Pharmaceuticals, Inc.

Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.
Two other patients (4401-01, 4402-01) had no meaningful change in proteinuria.
All three patients had COL4A4 nonsense mutations and background RAAS blockade.
Patient 4401-02's remission rebounded 1 month after treatment withdrawal.
Results from KOL Day on June 27, 2023 disclosed via 8-K filed July 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.